Drug development in the era of biologically rational, """"""""targeted therapeutics"""""""" in oncology requires specific expertise and complex skill sets. Far from previous paradigms in which drugs were plugged in to standard dose escalation schemata with dose limiting toxicity as the primary endpoint, today's investigators must develop creative trial designs which are appropriate for the specific agent and its specific targeted use. The investigator must be able to speak to the laboratory scientist working out the basic biological concepts, the pharmaceutical company which provides the drug, the analytic pharmacologists, biostatisticians, internal review boards and government regulators. Most importantly, the drug developer must be able to organize and lead a team effort, marshalling the resources at hand to design and execute a trial which is feasible, cost-effective, biologically and clinically sound, and which helps determine clinical and biological efficacy. The investigator must be able to glean information from the trial with which he or she can go back to the laboratory investigator and inform the basic investigation, forming an iterative process of discovery from bench to bedside to bench. Having acquired considerable unique expertise in the development of biologically driven therapies in myeloid malignancies, I am eager to spend more time mentoring developing investigators, transmitting my experience to a new generation. In the mentoring relationship, both mentor and trainee learn from each other and grow together. The Sidney Kimmel Comprehensive Cancer Center is a unique institution which provides outstanding resources for drug development in an academic center. I have organized a dynamic program focused on the translation of cutting edge basic science concerning the epigenetic regulation of gene expression to the rational non-cytotoxic treatment of myeloid malignancies. This program provides an outstanding venue for the training of young investigators;this K24 award will provide me with protected time to devote to that important endeavor and to further the accomplishment of my mission to develop effective therapies for this difficult group of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA111717-05
Application #
7649402
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2005-07-08
Project End
2010-06-30
Budget Start
2009-08-17
Budget End
2010-06-30
Support Year
5
Fiscal Year
2009
Total Cost
$150,160
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Uy, Natalie; Singh, Abhay; Gore, Steven D et al. (2017) Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opin Pharmacother 18:1213-1224
Zeidan, Amer M; Wang, Rong; Gross, Cary P et al. (2017) Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leuk Lymphoma 58:982-985
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Zeidan, Amer M; Smith, B Douglas; Carraway, Hetty E et al. (2017) A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br J Haematol 176:241-247
Podoltsev, Nikolai A; Stahl, Maximilian; Zeidan, Amer M et al. (2017) Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev 31:43-62
Ball, Brian; Zeidan, Amer; Gore, Steven D et al. (2017) Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma 58:1022-1036
Wang, Rong; Zeidan, Amer M; Yu, James B et al. (2017) Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. Prostate 77:437-445
Boyiadzis, Michael; Bishop, Michael R; Abonour, Rafat et al. (2016) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 4:90
Fletcher, Sean A; Cronin, Angel M; Zeidan, Amer M et al. (2016) Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 122:1209-15
Garcia-Manero, G; Gore, S D; Kambhampati, S et al. (2016) Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia 30:889-96

Showing the most recent 10 out of 80 publications